Need for more TB vaccine field sites.

Need for more TB vaccine field sites.

Efforts to control the tuberculosis (TB) epidemic have been challenged by both the geographical overlap with the HIV pandemic, and the emergence of multi - and extensively - drug-resistant strains of Mycobacterium tuberculosis. There is, therefore, an urgent global need for an improved vaccine. Howe...

Bibliográfalaš dieđut
Váldodahkki:	Mcshane, H
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	2009

Geahča maid

Towards new TB vaccines
Dahkki: Brazier, B, et al.
Almmustuhtton: (2020)

TB vaccines in clinical development
Dahkki: Ginsberg, A, et al.
Almmustuhtton: (2016)

TB vaccines in clinical development
Dahkki: Ginsburg, A, et al.
Almmustuhtton: (2016)

TB vaccines in clinical development
Dahkki: Ginsberg, AM, et al.
Almmustuhtton: (2016)

TB vaccine development: where are we and why is it so difficult?
Dahkki: Wilkie, M, et al.
Almmustuhtton: (2014)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
Dahkki: Mcshane, H
Almmustuhtton: (2008)

More is needed to end TB: commentary on the United Nations High-Level Meeting on TB
Dahkki: G. B. Migliori, et al.
Almmustuhtton: (2024-01-01)

A review of clinical models for the evaluation of human TB vaccines.
Dahkki: O'Shea, M, et al.
Almmustuhtton: (2016)

Progress and challenges in TB vaccine development
Dahkki: Voss, G, et al.
Almmustuhtton: (2018)

New TB vaccine granted orphan drug status.
Dahkki: Lang, T, et al.
Almmustuhtton: (2005)

Co-infection with HIV and TB: double trouble.
Dahkki: Mcshane, H
Almmustuhtton: (2005)

Evaluating aerosol administration of a candidate TB vaccine MVA85A
Dahkki: Thomas, Z, et al.
Almmustuhtton: (2014)

A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data.
Dahkki: McShane, H, et al.
Almmustuhtton: (2014)

A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data
Dahkki: McShane, H, et al.
Almmustuhtton: (2014)

Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy.
Dahkki: Minassian, A, et al.
Almmustuhtton: (2011)

Need for BCG Vaccination to Prevent TB in High-Incidence Countries and Populations
Dahkki: Shalini Pooransingh, et al.
Almmustuhtton: (2020-03-01)

A mycobacterial growth inhibition assay (MGIA) for bovine TB vaccine development
Dahkki: Pepponi, I, et al.
Almmustuhtton: (2017)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
Dahkki: Pathan, A, et al.
Almmustuhtton: (2012)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
Dahkki: Pathan, A, et al.
Almmustuhtton: (2012)

Development of a TB vaccine trial site in Africa and lessons from the Ebola experience
Dahkki: G. Kaguthi, et al.
Almmustuhtton: (2020-06-01)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants
Dahkki: Odutola, A, et al.
Almmustuhtton: (2012)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.
Dahkki: Odutola, A, et al.
Almmustuhtton: (2012)

Using an effective TB vaccination regimen to identify immune responses associated with protection in the murine model
Dahkki: Pinpathomrat, N, et al.
Almmustuhtton: (2021)

Progress and challenges in TB vaccine development [version 1; referees: 2 approved]
Dahkki: Gerald Voss, et al.
Almmustuhtton: (2018-02-01)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
Dahkki: Whelan, K, et al.
Almmustuhtton: (2009)

What research is needed to stop TB? Introducing the TB Research Movement.
Dahkki: Christian Lienhardt, et al.
Almmustuhtton: (2011-11-01)

Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy.
Dahkki: Angela M Minassian, et al.
Almmustuhtton: (2011-01-01)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
Dahkki: Tameris, M, et al.
Almmustuhtton: (2014)

Identification and evaluation of novel protective antigens for the development of a candidate TB subunit vaccine
Dahkki: Stylianou, E, et al.
Almmustuhtton: (2018)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses
Dahkki: Tameris, M, et al.
Almmustuhtton: (2014)

Differential cytokine levels in adults induced by a Novel candidate TB boost vaccine, MVA85A-according to previous BCG vaccination status
Dahkki: Owiafe, P, et al.
Almmustuhtton: (2012)

Update on TB Vaccine Pipeline
Dahkki: Carlos Martin, et al.
Almmustuhtton: (2020-04-01)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery.
Dahkki: Meyer, J, et al.
Almmustuhtton: (2013)

Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults
Dahkki: Harris, S, et al.
Almmustuhtton: (2011)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery
Dahkki: Meyer, J, et al.
Almmustuhtton: (2013)

Evaluation of immune correlates to TB vaccines
Dahkki: Marsay, L
Almmustuhtton: (2011)

Phase I trial evaluating the safety and immunogenicity of candidate TB vaccine MVA85A, delivered by aerosol to healthy M.tb-infected adults
Dahkki: Riste, M, et al.
Almmustuhtton: (2021)

Safety and efficacy of the Russian COVID-19 vaccine: more information needed
Dahkki: Bucci, E, et al.
Almmustuhtton: (2020)

Students Need More than Content Knowledge To Counter Vaccine Hesitancy
Dahkki: Star W. Lee, et al.
Almmustuhtton: (2023-08-01)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
Dahkki: Kathryn T. Whelan, et al.
Almmustuhtton: (2011-01-01)